Delirium Biomarkers in the Intensive Care Unit

重症监护病房中的谵妄生物标志物

• 批准号: 8723042
• 负责人: Babar A Khan
• 金额: $ 12.58万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8723042
• 关键词: Affect; Aging; Astrocytes; Attention; Award; Bioinformatics; Biological Assay; Biological Markers; Biological Process; Biometry; Blood; Blood specimen; C-reactive protein; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Cohort Studies; Complement; Complex; Coupled; Critical Care; Critical Illness; Data; Delirium; Development; Development Plans; Dexmedetomidine; Disease; Early identification; Enrollment; Ensure; Environment; Funding; Future; Growth Factor; Hospitals; IL8 gene; Indiana; Inflammation; Institutes; Insulin-Like Growth Factor I; Intensive Care Units; Interleukin-1; Interleukin-6; Intervention; K-Series Research Career Programs; Measures; Medical Informatics; Mentors; Molecular; Molecular Biology; Morbidity - disease rate; National Heart, Lung, and Blood Institute; Neurocognitive; Nonlinear Dynamics; Occupational; Pathologic; Patients; Protocols documentation; Randomized Clinical Trials; Research; Research Infrastructure; Research Personnel; Resources; Role; Sampling; Serum; Severities; Structure; Study of serum; Symptoms; System; TNF gene; Technology; Therapeutic Intervention; Therapeutic Studies; Time; Training; Translational Research; United States National Institutes of Health; Universities; Variant; Work; base; burden of illness; career; career development; clinical phenotype; data acquisition; didactic education; effective therapy; experience; inflammatory marker; insight; meetings; mortality; multidisciplinary; neuroprotection; patient oriented; patient population; skills; translational study

DESCRIPTION (provided by applicant): Delirium affects up to 80% of mechanically ventilated patients in the intensive care unit (ICU). Delirium duration and severity are independently associated with higher morbidity and mortality. Early identification of patients susceptible to prolonged delirium duration and higher delirium severity will help in instituting effective therapeutic interventions to reduce complications associated with delirium. A personalized approach utilizing biomarkers to identify vulnerable delirious patients prone to increased delirium duration and severity offers promise to curtail the disease burden. This proposal describes a career development plan that will enable Dr. Khan to develop expertise in patient-oriented translational clinical research by acquiring the necessary skills in biomarker technology, bio- informatics and biostatistics. The candidate will study serum biomarkers of inflammation, astrocyte activation and neuroprotection in the context of a large randomized clinical trial, the Pharmacological Management of Delirium (PMD) trial. Dr. Khan's proposed project is a cohort study embedded within the large trial benefiting from the diverse patient population, data acquisition resources, research personnel and other inherent strengths of an R01. The completion of the project will identify a unique set of candidate biomarkers for delirium duration and severity and will establish Dr. Khan as a neurocognitive critical care researcher. The proposed career development plan integrates; a) advanced coursework in molecular biology, biostatistics, and bioinformatics, b) participation in local/national meetings to develop expertise in translational research, c) a multidisciplinary mentored research experience, and d) a highly supportive research environment. This environment includes an internationally recognized NIH funded PMD Study Group, a distinguished Indiana University Center for Aging Research, a renowned Clinical and Translational Sciences Institute, and pioneers in Medical Informatics, the Regenstrief Institute. Overall, this career development award will ensure the necessary protected time required to advance the candidate's career in biomarker based translational critical care research. In addition, the award will provide critical support to guide future translational studies / R01 applications. Future studies will assess the impact of utilizing a personalized approach consisting of early identification of vulnerable delirious patients through serum biomarkers coupled with effective therapeutic interventions in decreasing the morbidity and mortality associated with ICU delirium.

描述（由申请人提供）：del妄影响着高达80％的重症监护病房（ICU）的机械通风患者。 ir妄持续时间和严重程度与更高的发病率和死亡率独立相关。早期鉴定患者容易长时间的ir妄持续时间和较高的ir妄严重程度，将有助于建立有效的治疗干预措施，以减少与del妄相关的并发症。一种个性化的方法利用生物标志物来识别容易发生del妄持续时间和严重程度的脆弱的妄想患者，这有望减轻疾病负担。 该建议描述了一项职业发展计划，该计划将使Khan博士通过获取生物标志物技术的必要技能来发展面向患者的转化临床研究的专业知识， 生物信息学和生物统计学。候选人将在一项大型随机临床试验（PMD）试验中，研究炎症，星形胶质细胞激活和神经保护的血清生物标志物。 Khan博士的提议项目是一项嵌入在大型试验中的队列研究，该研究受益于多样化的患者人群，数据获取资源，研究人员和R01的其他固有优势。该项目的完成将确定一套独特的候选生物标志物，以实现ir妄期限和严重性，并将Khan博士确立为神经认知的重症监护研究员。 拟议的职业发展计划集成； a）分子生物学，生物统计学和生物信息学的高级课程，b）参加本地/国家会议，以发展专业知识 在翻译研究中，c）多学科的指导研究经验，d）高度支持性的研究环境。该环境包括一个国际公认的NIH资助PMD研究小组，杰出的印第安纳大学衰老研究中心，著名的临床和转化科学研究所以及雷金斯研究所的医学信息学的先驱。 总体而言，该职业发展奖将确保促进候选人在基于生物标志物的转化重症监护研究中提高候选人职业所需的必要时间。此外，该奖项将为指导未来的翻译研究 / R01应用程序提供重要的支持。未来的研究将评估利用个性化方法的影响，该方法包括通过血清生物标志物以及有效的治疗干预措施来降低与ICU妄想相关的发病率和死亡率，包括早期识别脆弱的妄想患者。